Danish pharma huge Novo Nordisk teased promising early-stage trial benefits of its experimental weight loss tablet amycretin, sending the business’s stock surging.GLP-1 agonist medications, frequently termed GLP-1s, are injectable drugs that function by mimicking the GLP-1 hormone that the small intestine would make in reaction to meals, for each